Quick Takeaways
- NOVARTIS PHARMA AG filed SCHEDULE 13G/A for Erasca, Inc. Common stock, par value $0.0001 per share (ERAS).
- Disclosed ownership: 4.4%.
- Date of event: 31 Dec 2024.
NOVARTIS PHARMA AG - 31 Dec 2024 SCHEDULE 13G/A Report for Erasca, Inc. Common stock, par value $0.0001 per share (ERAS)
- Filing Manager
- NOVARTIS PHARMA AG
- Reporting Manager
- Novartis Pharma AG
- Symbol
- ERAS
- Shares outstanding
- 279,720,273 shares
- Disclosed Ownership
- 12,307,692 shares
- Ownership
- 4.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 12 Feb 2025, 17:02:05 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"NOVARTIS PHARMA AG disclosed 4.4% ownership in Erasca, Inc. Common stock, par value $0.0001 per share (ERAS) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 12 Feb 2025, 17:02.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Novartis Pharma AG | 4.4% | 12,307,692 | 0 | 12,307,692 | /s/ Christian Rehm | Christian Rehm | |
| Novartis AG | 4.4% | 12,307,692 | 0 | 12,307,692 | /s/ Christian Rehm | Christian Rehm |